170 related articles for article (PubMed ID: 6476844)
1. [Phase I-II study of 7-N-(P-hydroxyphenyl)-mitomycin C (KW2083, M83)].
Meguro S; Nagata T; Yokoyama K; Chinen T; Kobayashi T; Yamazaki H; Kuraishi Y; Ichiba ; Abe M; Isogai Y
Gan To Kagaku Ryoho; 1984 Sep; 11(9):1818-22. PubMed ID: 6476844
[TBL] [Abstract][Full Text] [Related]
2. [Phase I study of KW2083 7-N-(p-hydroxyphenyl) mitomycin C].
Gan To Kagaku Ryoho; 1982 Oct; 9(10):1844-50. PubMed ID: 7184379
[TBL] [Abstract][Full Text] [Related]
3. [Phase II study of KW2083 [7-N-(p-hydroxyphenyl)-mitomycin C] in patients with carcinoma of the lung and metastatic pulmonary tumor].
Shinkai T; Saijo N; Tominaga K; Eguchi K; Shimizu E; Shibuya M; Shimabukuro Z
Gan To Kagaku Ryoho; 1983 Mar; 10(3):834-9. PubMed ID: 6882001
[TBL] [Abstract][Full Text] [Related]
4. [Phase II study of KW 2083 [7-N-(p-hydroxyphenyl)-mitomycin C] in patients with various cancers].
Nishi I; Yokoyama T; Nakao I; Harashima S; Ohashi Y; Kanko T; Saito T
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 1):2513-9. PubMed ID: 6508315
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of 7-N-(p-hydroxyphenyl)-mitomycin C (KW2083) in patients with advanced non-small cell carcinoma of the lung and metastatic pulmonary tumors.
Shinkai T; Saijo N; Tominaga K; Eguchi K; Shimizu E; Sasaki Y; Fujita J; Futami H; Hoshi A
Jpn J Clin Oncol; 1985 Mar; 15(1):61-5. PubMed ID: 3981815
[TBL] [Abstract][Full Text] [Related]
6. [A clinical trial of a new mitomycin C derivative, KW-2083 (7-N-(p-hydroxyphenyl)-mitomycin C)].
Takahashi K; Yokoyama M; Takahashi H; Wakui A
Gan To Kagaku Ryoho; 1985 Sep; 12(9):1787-93. PubMed ID: 4037809
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of 7-N-(p-hydroxyphenyl)-mitomycin C.
Meguro S; Nagata T; Yokoyama K; Chinen T; Yamazaki H; Kobayashi T; Isogai Y; Ogawa M
Invest New Drugs; 1984; 2(4):381-5. PubMed ID: 6511242
[TBL] [Abstract][Full Text] [Related]
8. [A phase I trial of 4'-epiadriamycin].
Ogawa M; Ikeda K; Inagaki J; Horikoshi N; Inoue K; Nakada K; Usui N; Okada Y; Adachi K; Tada A
Gan To Kagaku Ryoho; 1984 Apr; 11(4):926-9. PubMed ID: 6586111
[TBL] [Abstract][Full Text] [Related]
9. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
10. [Phase I and pharmacokinetic study of KRN8602, a new morpholino anthracycline].
Tabata M; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Nagamine D; Shinagawa K; Fukutani H; Hirano A; Mizunuma N
Gan To Kagaku Ryoho; 1989 Jul; 16(7):2361-6. PubMed ID: 2546503
[TBL] [Abstract][Full Text] [Related]
11. [Phase I trial of 4'-O-tetrahydropyranyl-doxorubicin (THP)--a multi-institutional cooperative study].
Wakui A; Yokoyama M; Konno K; Nakai Y; Sakano T; Koyama Y; Imamura Y; Nakajima O; Niijima T; Akaza H
Gan To Kagaku Ryoho; 1985 Jan; 12(1):118-24. PubMed ID: 3966806
[TBL] [Abstract][Full Text] [Related]
12. A phase I-II study of continuous 5-day infusion mitomycin-C.
Yap HY; Valdivieso M; Blumenschein G; Hortobagyi G; Bedikian A
Am J Clin Oncol; 1983 Feb; 6(1):109-12. PubMed ID: 6404154
[TBL] [Abstract][Full Text] [Related]
13. [Phase I study of raltitrexed (ZD-1694)].
Horikoshi N; Aiba K; Fukuoka M; Akazawa S; Sakata Y; Furuse K; Kanamaru R; Kudoh S; Konishi T; Kurihara M; Niitani H; Furue H; Tsukagoshi S; Taguchi T; Yoshida S; Ota K; Kotake T; Wakui A
Gan To Kagaku Ryoho; 1998 Nov; 25(13):2075-84. PubMed ID: 9838910
[TBL] [Abstract][Full Text] [Related]
14. [Phase I study of a new antitumor antibiotic, neothramycin].
Kimura K; Ogawa M; Wakui A; Oguro M; Koyama Y; Saito T; Furue H; Ota K; Yamada K; Hoshino A; Nakamura T; Masaoka T; Taguchi T; Kimura I; Hattori T
Gan To Kagaku Ryoho; 1982 May; 9(5):924-9. PubMed ID: 7184435
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
16. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
[TBL] [Abstract][Full Text] [Related]
17. [The clinical phase I study of TNP-351. The TNP-351 Research Committee].
Taguchi T; Niitani H; Furue H; Tsukagoshi S; Kanamaru R; Hasegawa K; Akazawa S; Yoneda S; Tominaga T; Sasaki T
Gan To Kagaku Ryoho; 1995 Feb; 22(2):259-71. PubMed ID: 7857102
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
Recchia F; Sica G; De Filippis S; Rosselli M; Saggio G; Guerriero G; Pompili P; Rea S
Anticancer Res; 2000; 20(3B):1985-90. PubMed ID: 10928138
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
Wolff I; Bench K; Beijnen JH; Bruntsch U; Cavalli F; de Jong J; Groot Y; van Tellingen O; Wanders J; Sessa C
Clin Cancer Res; 1996 Oct; 2(10):1717-23. PubMed ID: 9816122
[TBL] [Abstract][Full Text] [Related]
20. [Phase I clinical study of MX2 (KRN 8602)].
Majima H
Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):359-64. PubMed ID: 2310202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]